Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CEVEC Signs License Agreement with Yuhan of South Korea

Published: Friday, December 21, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
License will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems.

CEVEC Pharmaceuticals and Yuhan Corporation have announced the signing of a CAP-Technology license agreement.

The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.

CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.

The Technology allows for superior protein yields in a shorter time frame than traditional methods.

“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression systems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases” stated Wolfgang Kintzel, CEO at CEVEC.

Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of CEVEC’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CEVEC and BioLamina Combine Technology Leadership
CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies.
Friday, November 06, 2015
Completion of a “First in Human” Clinical Phase I Study Using CAP® Cells
Consortium reported safe completion of clinical study with recombinant human Alkaline Phosphatase (hRESCAP®).
Tuesday, November 05, 2013
CEVEC and VPM Sign Exclusive License Agreement
Agreement on the clinical development of a novel human CMV vaccine.
Friday, January 04, 2013
CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices
Paragon Bioservices to perform process development for the contract manufacturing of recombinant proteins and antibodies.
Friday, August 03, 2012
CEVEC Raises €6M to Grow CAP® Technology Based Protein and Vaccine Business
CEVEC announces closing of €6M financing round.
Tuesday, August 09, 2011
CAP Cells Suitable for Commercial Vaccine Production?
CEVEC Pharmaceuticals has announced that CAP cells produce high virus titers upon infection with influenza strains.
Wednesday, September 29, 2010
CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies
Both the companies will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community.
Wednesday, August 18, 2010
Pevion Biotech and CEVEC Pharmaceuticals Sign Exclusive License Option Agreement
Pevion to use CEVEC’s transient CAP-T™ cell expression technology to manufacture protein antigen for vaccination against infectious disease.
Wednesday, May 26, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!